Advanced search
Publication Cover
Postgraduate Medicine Volume 132, 2020 - Issue 4
Submit an article Journal homepage
11,794
Views
12
CrossRef citations to date
0
Altmetric
Clinical focus: Diabetes - Original Research

Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes

Ildiko Lingvaya Department of Internal Medicine/Endocrinology and Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX, USACorrespondence[email protected]
View further author information
,
Nadine Beetzb Global Clinical Operations, Early Trials, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, GermanyORCID Iconhttps://orcid.org/0000-0002-1071-7000View further author information
ORCID Icon,
Regina Sennewaldb Global Clinical Operations, Early Trials, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, GermanyORCID Iconhttps://orcid.org/0000-0002-6499-0942View further author information
ORCID Icon,
Annette Schuler-Metzc Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, GermanyORCID Iconhttps://orcid.org/0000-0002-0332-7709View further author information
ORCID Icon,
Julia Bertulisc Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, GermanyORCID Iconhttps://orcid.org/0000-0002-4863-6003View further author information
ORCID Icon,
Christina Loleyd Biostatistics and Data Sciences, Clinical Statistics, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, GermanyView further author information
,
Benjamin Langd Biostatistics and Data Sciences, Clinical Statistics, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, GermanyView further author information
,
Caroline Lippertc Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, GermanyView further author information
,
Jisoo Leee Clinical Development & Cardiometabolism and Respiratory Medicine, Boehringer Ingelheim International GmbH, Ingelheim, GermanyView further author information
,
Linda Shapiro Manningf Clinical Development & Medical Affairs - Cardiometabolism, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USAORCID Iconhttps://orcid.org/0000-0001-8229-381XView further author information
ORCID Icon &
Derek Teradaf Clinical Development & Medical Affairs - Cardiometabolism, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USAView further author information
 show all
Pages 337-345 | Received 05 Mar 2020, Accepted 30 Mar 2020, Published online: 04 May 2020

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Nobuya Inagaki, Takaaki Nishimoto, Yoichi Nishiya & Daisuke Nitta. (2023) Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study. Expert Opinion on Drug Safety 22:2, pages 153-163.
Read now

Articles from other publishers (11)

Xueqin Xie, Changchun Wu, Yuduo Hao, Tianyu Wang, Yuhe Yang, Peiling Cai, Yang Zhang, Jian Huang, Kejun Deng, Dan Yan & Hao Lin. (2023) Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review. Frontiers in Endocrinology 14.
Crossref
Evelyn PenaAlfredo InattiAnyoli TalyJosé Gregorio ChacónXenon Serrano-Martin. (2023) Bioequivalence assessment of two formulations of empagliflozin in healthy adult subjects. American Journal of Pharmacotherapy and Pharmaceutical Sciences 2, pages 19.
Crossref
Qing Li, Xiaoyan Deng, Yan-Jun Xu & Lin Dong. (2023) Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants. Journal of Medicinal Chemistry 66:17, pages 11593-11631.
Crossref
Linong Ji, Yibin Lu, Qifu Li, Liujun Fu, Yong Luo, Tao Lei, Ling Li, Shandong Ye, Bimin Shi, Xiyan Li & Thomas Meinicke. (2023) Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III , randomized, double‐blind, placebo‐controlled, parallel study . Diabetes, Obesity and Metabolism 25:7, pages 1839-1848.
Crossref
Yan-Yu Lin, Shuen-Fu Weng, Chung-Huei Hsu, Chen-Ling Huang, Yu-Pei Lin, Min-Chun Yeh, A-Young Han & Yu-Shan Hsieh. (2022) Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus. Frontiers in Medicine 9.
Crossref
Panke Zhang, Jingxi Meng, Mingliang Duan, Dan Li & Ruixin Wang. (2022) Efficacy of Yishen Huashi Granules Combined with Linagliptin Tablets on Blood Glucose and Renal Function in Patients with Type 2 Diabetic Nephropathy. Computational Intelligence and Neuroscience 2022, pages 1-7.
Crossref
Aya A. Marie, Mohamed M. Salim, Amira H. Kamal, Sherin F. Hammad & Mahmoud M. Elkhoudary. (2022) Analytical quality by design based on design space in reversed-phase-high performance liquid chromatography analysis for simultaneous estimation of metformin, linagliptin and empagliflozin. Royal Society Open Science 9:6.
Crossref
Santenna Chenchula, Shoban Babu Varthya & R. Padmavathi. (2022) Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies. Current Diabetes Reviews 18:4.
Crossref
Ha Eun Choi, Ji Won Lee, Nam Kyung Je & Kyeong Hye Jeong. (2022) Use of SGLT2 inhibitor/metformin fixed dose combination in Korea. Korean Journal of Clinical Pharmacy 32:1, pages 13-19.
Crossref
Mara A Darian. (2021) Starting triple oral hypoglycemic agent therapy in poorly controlled type 2 diabetes is a suitable therapeutic strategy to lower HbA1c when insulin therapy is not desired. Clinical Research In Practice: The Journal of Team Hippocrates 7:1.
Crossref
. (2020) Trijardy XR—A New 3-Drug Combination for Type 2 Diabetes. JAMA 324:23, pages 2437.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.